Compounded semaglutide is not the same thing as the approved brand-name drug. At Longevity Benchmark, we evaluate prescription therapies by examining what published evidence and regulatory documentation substantiate.

Brand-name semaglutide products undergo federal review for safety, effectiveness, and quality before distribution, whereas compounded formulations do not receive pre-market agency evaluation. This distinction affects the evidence base, product documentation, and clinical verification available to patients and prescribers.

The Verdict

Brand-name semaglutide products are FDA-approved medications supported by pre-market review of safety, quality, and clinical efficacy, with published outcomes from trials including STEP 1 and SELECT. Compounded semaglutide preparations are produced under separate statutory frameworks for compounding pharmacies and outsourcing facilities, and FDA does not evaluate them for safety, effectiveness, or quality before they reach patients. The published clinical trials evaluated manufacturer-supplied commercial formulations rather than compounded preparations, leaving the efficacy and safety of compounded alternatives unverified in peer-reviewed studies. Whether a patient receives an FDA-approved commercial drug or a compounded preparation is a clinical and legal decision that belongs entirely to the patient, their prescriber, and their dispensing pharmacist.

Compounded semaglutide vs Brand-name semaglutide, Side by Side

AttributeCompounded semaglutideBrand-name semaglutide
FDA pre-market review of safety, effectiveness and quality FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed Reviewed and approved by FDA before commercial distribution
Who prepares it Prepared by a compounding pharmacy operating under section 503A or an outsourcing facility registered under section 503B Manufactured by Novo Nordisk
FDA-reviewed prescribing information Does not come with FDA-reviewed prescribing information or labelling Supplied with FDA-reviewed prescribing information
Clinical trials studying the product as supplied No published clinical trials have evaluated compounded semaglutide preparations Evaluated in published randomized controlled trials including STEP 1 and SELECT
Boxed warning documentation Not documented in FDA-reviewed labelling for compounded preparations Prescribing information carries a boxed warning about thyroid C-cell tumours observed in rodents
What the patient can verify Preparation details from the dispensing compounder, without FDA review FDA-reviewed prescribing information and approved commercial packaging
Where to check Compounding questions and answers on the FDA website Approved prescribing information documents

What Compounding Is and What FDA Does Not Review

Brand-name semaglutide products are FDA-approved drugs whose manufacturing, labelling, and evidence FDA has reviewed. In contrast, compounded preparations are made by a pharmacy or outsourcing facility, and FDA does not review compounded drugs for safety, effectiveness, or quality before they reach a patient. According to the FDA compounding questions and answers, compounding is combining, mixing, or altering ingredients to create a medication tailored to an individual patient's needs.

Because compounded medications do not undergo pre-market agency review, they do not receive the formal safety and efficacy evaluation that commercial pharmaceuticals receive. Federal authorities do not evaluate compounded formulations for clinical efficacy, identity, or quality prior to marketing. When patients receive a compounded formulation, that specific preparation has not been tested in clinical trials to verify whether its outcomes match commercial formulations.

The Two Categories of Compounder Under Federal Law

United States law establishes two separate legal categories for facilities that prepare compounded medications. Under federal statutes detailed on the FDA compounding laws and policies page, the law distinguishes compounding pharmacies operating under section 503A from outsourcing facilities registered under section 503B. These entities operate under separate legal provisions and are subject to different statutory requirements.

The FDA compounding questions and answers page explains how federal oversight applies to these distinct compounder classifications. Specific facility inspection histories, state licensing parameters, and individual compounder certifications are outside what this benchmark verifies. The FDA compounding questions and answers page and the FDA compounding laws and policies page are the sources this page relies on for that distinction.

What the Absence of Reviewed Labelling Means

Semaglutide is a GLP-1 receptor agonist manufactured by Novo Nordisk. In the United States, semaglutide is approved and marketed under three brand names with different approved uses. Each commercial formulation is distributed with comprehensive, FDA-reviewed prescribing information that defines its clinical parameters and safety profile.

A compounded semaglutide preparation does not arrive with prescribing information reviewed by the FDA. Brand-name semaglutide products are FDA-approved, whereas the regulatory agency does not review compounded drugs for safety, effectiveness or quality before they are marketed. In addition, every clinical trial cited across this guide evaluated an approved manufacturer product made by Novo Nordisk instead of an unreviewed compounded preparation.

That difference in regulatory review determines the documentation packaged with an approved prescription drug. As detailed in our comparison of Ozempic vs Wegovy, Ozempic's approved use category is type 2 diabetes, while Wegovy's approved category is chronic weight management. The approved United States prescribing information for both commercial Novo Nordisk products carries a boxed warning regarding thyroid C-cell tumours observed in rodent studies.

A compounded preparation arrives without an FDA-reviewed package insert to establish approved use categories or communicate standardized warnings. United States law distinguishes 503A compounding pharmacies from 503B outsourcing facilities, and the two are subject to different requirements. What a compounded preparation is or is not supplied with is set by the facility that prepared it, and none of it has been through the federal review that an approved product's labelling has.

Boxed Warning and Commercial Documentation

Commercial pharmaceuticals include verified documentation describing evaluated safety signals and approved prescribing conditions. The approved US prescribing information for Ozempic and Wegovy carries a boxed warning about thyroid C-cell tumours observed in rodents. Compounded preparations do not carry FDA-reviewed prescribing information, leaving that documentation absent from compounded containers.

For exact wording, contraindications, and the full warnings list, readers should consult the approved prescribing information PDFs directly. This benchmark does not paraphrase warnings, list clinical contraindications, or summarize precautions that appear in official documentation.

What the Published Evidence Covers and Leaves Out

Every clinical trial evaluating semaglutide was conducted using the manufacturer's commercial product at studied doses under controlled protocols. No published clinical trials have evaluated compounded semaglutide preparations. Consequently, the weight-loss, glycemic, and cardiovascular figures frequently cited in discussions of compounded semaglutide are borrowed from trials that did not evaluate compounded formulations. No completed trial has tested a microdose regimen either. On the approved labels, initial dose escalation exists to reduce gastrointestinal adverse reactions, and the pens carry explicit prohibitions against splitting doses. The FDA has documented severe dosing errors from compounded alternatives.

In the STEP 1 trial, semaglutide 2.4 mg versus placebo was evaluated over 68 weeks in 1,961 adults with a BMI of 30 or greater, or 27 or greater with a weight-related coexisting condition, without diabetes. Participants in the semaglutide 2.4 mg group achieved a mean weight change of -14.9% compared to -2.4% with placebo, representing a treatment difference of -12.4 percentage points (95% CI -13.4 to -11.5, P<0.001), with weight loss of -15.3 kg versus -2.6 kg. In that trial, 86.4% of participants on semaglutide reached 5% or more body weight reduction versus 31.5% on placebo, 69.1% reached 10% or more versus 12.0%, and 50.5% reached 15% or more versus 4.9%. Novo Nordisk funded the STEP 1 trial.

Cardiovascular outcomes were evaluated in the SELECT trial, which enrolled 17,604 patients aged 45 or older with preexisting cardiovascular disease and a BMI of 27 or greater without diabetes over a mean follow-up of 39.8 months. The primary cardiovascular end point occurred in 6.5% of patients in the semaglutide 2.4 mg group versus 8.0% in the placebo group, with a hazard ratio 0.80 (95% CI 0.72 to 0.90, P<0.001). Permanent discontinuation due to adverse events occurred in 16.6% of the semaglutide group compared to 8.2% of the placebo group (P<0.001). Novo Nordisk funded the SELECT trial. These outcomes demonstrate what the commercial product achieved, but they provide no clinical data regarding compounded preparations.

Documented Adverse Events and Safety Profiles

Adverse event reporting across major clinical trials documents specific tolerability profiles for commercial incretin therapies. Across the published clinical trials for semaglutide and tirzepatide, the most common adverse events were gastrointestinal, described as mostly mild to moderate in severity and occurring primarily during dose escalation. Because compounded preparations have not been evaluated in comparable trials, their adverse event rates have not been established in peer-reviewed clinical studies.

In the SURPASS-2 trial, reported rates of nausea were 17% to 22% across tirzepatide doses compared to 18% with semaglutide 1 mg. Diarrhea occurred in 13% to 16% of patients receiving tirzepatide versus 12% on semaglutide, while vomiting was reported in 6% to 10% on tirzepatide and 8% on semaglutide. Hypoglycemia with blood glucose below 54 mg/dL occurred in 0.6% (5 mg), 0.2% (10 mg), and 1.7% (15 mg) of tirzepatide patients and in 0.4% of semaglutide patients. Serious adverse events were reported in 5% to 7% of tirzepatide patients and 3% of semaglutide patients.

Discontinuation rates due to adverse events were specifically tracked across major obesity studies. In the STEP 1 trial, 4.5% of participants in the semaglutide group discontinued treatment because of gastrointestinal events compared to 0.8% in the placebo group. In the SURMOUNT-1 trial, adverse events caused treatment discontinuation in 4.3% (5 mg), 7.1% (10 mg), and 6.2% (15 mg) of participants on tirzepatide versus 2.6% on placebo. The approved US prescribing information for all four brands carries a boxed warning about thyroid C-cell tumours observed in rodents.

Shortages and the Conversation Around Compounding

Drug shortages frequently prompt discussions regarding compounded alternatives. Information on the FDA drug shortages FAQ page defines a drug shortage as a period when the total supply of all clinically interchangeable versions of an FDA-regulated drug is inadequate to meet current or projected demand. Federal authorities monitor pharmaceutical supply chains and maintain official lists of medications experiencing documented supply constraints.

However, this benchmark does not track the current shortage status of any specific product, nor does it publish dates when medications entered or left federal shortage lists. The FDA drug shortages FAQ is the place to check to verify the real-time supply status of any pharmaceutical product.

What Can Be Verified Before Use

Patients evaluating brand-name semaglutide can inspect official documentation that has completed federal regulatory review. Every commercial package of Ozempic or Wegovy includes approved prescribing information detailing authorized uses, clinical trial outcomes, and safety parameters. Patients and clinicians can verify these parameters by examining the official prescribing information documents published online.

Patients receiving compounded semaglutide cannot verify their medication against FDA-reviewed product labelling. Compounded preparations do not come with FDA-evaluated safety inserts, standardized package documentation, or approved indications. Pricing, insurance coverage, copay assistance, and specific pharmacy pricing programs are outside what this page can verify.

What This Comparison Leaves to Clinical Care

This comparison does not evaluate individual telehealth companies, compounding pharmacies, or commercial sellers. It does not recommend starting, stopping, switching, or dosing any medication. Decisions regarding the choice between commercial FDA-approved medications and compounded preparations require individualized evaluation by a licensed healthcare professional.

Prescribing decisions depend on clinical history, individual medical necessity, diagnostic evaluations, and regulatory parameters. The choice between an approved brand-name medication and an individual compounded preparation belongs to the patient, their prescribing clinician, and their pharmacist.

Frequently Asked Questions

Is compounded semaglutide FDA approved?

No. Compounded semaglutide is not approved by the FDA. Federal law does not require FDA to review compounded drugs for safety, effectiveness, or quality before they are marketed. In contrast, brand-name semaglutide products undergo pre-market evaluation and approval by the agency.

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Compounded semaglutide is not the same as Ozempic or Wegovy. Ozempic and Wegovy are commercial, FDA-approved medications manufactured by Novo Nordisk, accompanied by FDA-reviewed prescribing information and standardized packaging. Compounded semaglutide is prepared by a pharmacy or outsourcing facility without FDA pre-market evaluation or approved labelling.

Do the weight-loss trial results apply to compounded semaglutide?

No. The published weight-loss trial results, such as the STEP 1 trial, evaluated the manufacturer's specific commercial product at studied doses under controlled protocols. None of the published clinical trials evaluated compounded semaglutide preparations. Claimed weight-loss figures for compounded formulations are borrowed from studies that did not test compounded drugs.

What is the difference between a 503A pharmacy and a 503B outsourcing facility?

United States law establishes two distinct categories for compounding facilities under the Federal Food, Drug, and Cosmetic Act. Section 503A applies to traditional compounding pharmacies that compound medications for individual patients pursuant to patient-specific prescriptions. Section 503B applies to registered outsourcing facilities that operate under separate statutory provisions and federal requirements.

Why did compounded semaglutide become common?

Compounded semaglutide became widely discussed when demand for GLP-1 receptor agonists exceeded available supplies. The FDA drug shortages FAQ explains that a shortage occurs when total supply is inadequate to meet current or projected demand. Federal statutory provisions allow compounding facilities to prepare medications under specific conditions during supply constraints, though real-time shortage status varies.

How can I check what is in a compounded preparation?

A compounded preparation does not come with FDA-reviewed labelling, so there is no reviewed document to check it against. Because compounded drugs do not come with FDA-reviewed prescribing information or standardized packaging, details regarding formulation, ingredients, and preparation methods are maintained by the compounder. The FDA does not verify the composition or potency of individual compounded preparations before distribution.

Does compounded semaglutide have the same warnings?

Compounded semaglutide does not come with FDA-approved prescribing information or official boxed warnings. However, the active ingredient semaglutide is associated with specific risks. The approved US prescribing information for brand-name Ozempic and Wegovy carries a boxed warning regarding thyroid C-cell tumours observed in rodents. Readers should consult the approved prescribing information for the full warnings list.

Related